Ultragenyx: Still Lacking Appeal Despite 'Commercial-First' Pivot

I've long been a bear on Ultragenyx Pharmaceutical Inc. (RARE). My first “Sell” recommendation came in November 2023. I was covering an osteogenesis imperfecta [OI] biologic that the company was developing in collaboration with Mereo BioPharma

CryptoAlerta — análise de criptomoedas e mercado em tempo real